Paraganglioma Clinical Trials

66 clinical trials for Paraganglioma across international registries, including 16 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Using the EHR to Advance Genomic Medicine Across a Diverse Health System — RECRUITING · NA
• Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). — RECRUITING · PHASE1
• Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors — RECRUITING · PHASE1
• Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma — RECRUITING · PHASE2
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors — RECRUITING · PHASE1
• In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma — RECRUITING · PHASE1
• Institutional Registry of Rare Diseases — RECRUITING
• 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. — RECRUITING · PHASE4
• Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions — RECRUITING
• Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma — RECRUITING
• The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma — RECRUITING · PHASE4
• Hereditary Pheochromocytoma Assessment of Tumour Immunologies — RECRUITING
• "Receptor Radionuclide Therapy With 177Lu-DOTATOC — RECRUITING · PHASE2
• Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients — RECRUITING
• 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor — RECRUITING · PHASE1
• Multicenter Pheochromocytoma and Paraganglioma Evaluation — RECRUITING · NA
• Zanzalintinib in Unresectable and Progressive MPGGs — NOT_YET_RECRUITING · PHASE2
• Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma — COMPLETED
• 211At-MABG in Adults With Advanced Neuroendocrine Cancers — NOT_YET_RECRUITING · PHASE1
• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• DOTATOC PET/CT for Imaging NET Patients — ACTIVE_NOT_RECRUITING
• Prospective Cohort Study of Pheochromocytoma/Paraganglioma — NOT_YET_RECRUITING
• Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma — ACTIVE_NOT_RECRUITING · PHASE2
• LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer — TERMINATED · PHASE2
• Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs — ACTIVE_NOT_RECRUITING · PHASE2
• Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma — COMPLETED · NA
• A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma — TERMINATED · PHASE1
• Prognostic's Factors of Head and Neck Paragangliomas Evolution — ACTIVE_NOT_RECRUITING
• Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study — COMPLETED · PHASE2
• 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System — WITHDRAWN · PHASE2
• Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics — COMPLETED
• Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma — COMPLETED · PHASE2
• The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs) — OTHER
• Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROBAT) — TERMINATED · NA
• Exendin PET/CT for Imaging of Paragangliomas — OTHER
• Fluorescence Guided Minimally-Invasive Resection Of Abdominal Paragangliomas Using Indocyanine Green — OTHER
• Preoperative Alpha Blockade for Pheochromocytoma — COMPLETED · PHASE3
• Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma — TERMINATED
• F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma — TERMINATED
• A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL — OTHER · PHASE2
• A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL — OTHER · PHASE2
• Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study — NOT_YET_RECRUITING
• Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. — WITHDRAWN · PHASE2
• Expanded Access Protocol Using 131I-MIBG — OTHER
• 18F-FDOPA PET in Neuroendocrine Tumours — TERMINATED
• Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma — OTHER
• Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma — COMPLETED
• Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents — WITHDRAWN · PHASE1
• Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease — OTHER

Refine this search